Advanced Filters
noise
Found 64,783 clinical trials
R Rodney Cheng-En Hsieh, MD, PhD

Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%. Proton radiotherapy (RT), known for its precision and tissue-sparing advantages, has demonstrated improved survival outcomes and reduced toxicity compared to X-ray RT. Retrospective data …

18 years of age All Phase 2
J Josephine Savard

Psychological Treatment for Paraphilic Disorders

The goal of this randomized study is to learn if a psychological intervention can treat help-seeking patients with paraphilic disorders. The main questions it aims to answer are: Is psychological therapy helpful for the reduction of problematic sexual behaviors among patients with paraphilic disorders? Is psychological helpful for the reduction …

18 years of age All Phase N/A
A Aliya Lalji

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

This research is being done to test the feasibility of 24-48 hours of water-only fasting to improve delivery of 4 cycles of chemotherapy in those receiving breast cancer treatment either before or after surgery.

18 years of age Female Phase N/A
K Katherine A Scott, BSN

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.

21 - 49 years of age Female Phase 3
M Marie-Madeleine Dolmans, MD, PhD

EUmetriosis: Insights Into the Pathogenesis of Endometriosis

This study investigates epigenetic changes in menstrual effluent and plasma from women with endometriosis to identify potential non-invasive diagnostic biomarkers for the disease.

18 - 56 years of age Female Phase N/A
P Pierre PELISSIER

Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study

The goal of this clinical trial is to investigate if new, early biomarkers of the disease are available in presymptomatic genetic carriers of Huntington's diesase compared to healthy subjects. The main questions it aims to answer are: Does functional brain MRI is able to detect early biomarkers of the disease …

18 - 70 years of age All Phase N/A
J Jiangdong Sui, Ph.D, M. D.

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

This is a multicenter, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.

18 - 65 years of age All Phase 2
E Erik A Jensen, MD

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia

The goal of this clinical trial is to learn if transpyloric tube feeding (feeding directly into the small intestine) versus gastric tube feeding tolerably and effectively reduces gastroesophageal reflux in infants born premature who have been diagnosed with bronchopulmonary dysplasia. The main questions this trial aims to answer are: Does …

1 - 12 years of age All Phase N/A
N Nipaporn Wannaprom, Dr

Scapular Repositioning for Neck Pain and Scapular Dysfunction

This randomized controlled trial is designed to evaluate the effects of scapular repositioning in individuals with neck pain and scapular dysfunction. The main questions it aims to answer are: Does scapular repositioning reduce neck pain, increase range of motion, and improve joint position sense and pressure pain threshold? Which type …

18 - 59 years of age All Phase N/A
P Pei Ding

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.

18 - 75 years of age All Phase 1

Simplify language using AI